

Hisao Imai

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8663748/hisao-imai-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131
papers

2,286
citations

26
h-index

42
g-index

149
ext. papers

2,661
ext. citations

3.6
avg. IF

4.22
L-index

#	Paper	IF	Citations
131	Effects of adding a neurokinin-1 receptor antagonist to 5mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.. <i>BMC Cancer</i> , 2022 , 22, 310	4.8	
130	Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. <i>Frontiers in Oncology</i> , 2021 , 11, 610952	5.3	1
129	Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial. <i>Oncologist</i> , 2021 , 26, e1066-e1072	5.7	2
128	Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing Mutations. <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	1
127	Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials. <i>BMC Cancer</i> , 2021 , 21, 832	4.8	1
126	Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 444-450	2.8	1
125	Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression $\geq 0\%$ on first-line pembrolizumab. <i>Thoracic Cancer</i> , 2021 , 12, 304-313	3.2	6
124	Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer. <i>International Journal of Clinical Oncology</i> , 2021 , 26, 104-110	4.2	2
123	Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy. <i>Oncology</i> , 2021 , 99, 562-570	3.6	2
122	Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure. <i>Thoracic Cancer</i> , 2021 , 12, 864-873	3.2	4
121	Re: INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer. <i>Pathology</i> , 2021 , 53, 292-293	1.6	2
120	Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021 , 12, 1171-1179	3.2	1
119	Tumor immunity is related to F-FDG uptake in thymic epithelial tumor. <i>Cancer Medicine</i> , 2021 , 10, 6317-6326	4.36	2
118	Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer. <i>Cancer Medicine</i> , 2021 , 10, 6971-6984	4.8	3
117	Course of postoperative relapse in non-small cell lung cancer is strongly associated with post-progression survival. <i>Thoracic Cancer</i> , 2021 , 12, 2740-2748	3.2	1
116	Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine Carcinoma. <i>Chemotherapy</i> , 2021 , 66, 65-71	3.2	1
115	Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study.. <i>Current Oncology</i> , 2021 , 29, 163-172	2.8	1

114	Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. <i>Investigational New Drugs</i> , 2020 , 38, 1854-1861	4.3	6
113	Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
112	Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment. <i>Thoracic Cancer</i> , 2020 , 11, 2188-2195	3.2	8
111	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 761-771	3.5	19
110	Prognostic Significance of Glucose Metabolism as GLUT1 in Patients with Pulmonary Pleomorphic Carcinoma. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
109	A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101. <i>International Journal of Clinical Oncology</i> , 2020 , 25, 867-875	4.2	
108	Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study. <i>Supportive Care in Cancer</i> , 2020 , 28, 4825-4831	3.9	3
107	Post-progression survival is strongly linked to overall survival in refractory small-cell lung cancer patients who received amrubicin. <i>Journal of Cancer Research and Therapeutics</i> , 2020 , 16, 764-770	1.2	0
106	Metachronous bilateral breast metastases of a lung neuroendocrine tumor: A case report. <i>Molecular and Clinical Oncology</i> , 2020 , 13, 53	1.6	2
105	Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma. <i>Anticancer Research</i> , 2020 , 40, 261-269	2.3	3
104	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged 75 years) with non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 457-466	4.9	10
103	Patients Self-Assessment of the Symptoms and Impact of Opioid-Induced Constipation: Results From a Prospective Observational Cohort Study of Japanese Patients With Cancer. <i>Journal of Pain and Symptom Management</i> , 2020 , 59, 1043-1051.e2	4.8	3
102	Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab. <i>Thoracic Cancer</i> , 2020 , 11, 3521-3527	3.2	1
101	Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer. <i>Chemotherapy</i> , 2020 , 65, 21-28	3.2	2
100	Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy. <i>Lung Cancer</i> , 2020 , 148, 122-128	5.9	3
99	Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged 75 years) with non-small cell lung cancer: A retrospective analysis. <i>Thoracic Cancer</i> , 2020 , 11, 2867-2876	3.2	2
98	Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC. <i>Anticancer Research</i> , 2020 , 40, 1571-1578	2.3	
97	Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. <i>Thoracic Cancer</i> , 2019 , 10, 2200-2208	3.2	5

96	Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. <i>Oncologist</i> , 2019 , 24, 593-e170	5.7	8
95	Incidence of opioid-induced constipation in Japanese patients with cancer pain: A prospective observational cohort study. <i>Cancer Medicine</i> , 2019 , 8, 4883-4891	4.8	12
94	A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. <i>BMC Cancer</i> , 2019 , 19, 528	4.8	22
93	An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019 , 39, 2483-2491	2.3	3
92	Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. <i>Japanese Journal of Clinical Oncology</i> , 2019 , 49, 671-675	2.8	9
91	Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 655-660	3.5	4
90	Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma. <i>Cancers</i> , 2019 , 11,	6.6	3
89	Factors affecting the performance of activities of daily living in patients with advanced cancer undergoing inpatient rehabilitation: results from a retrospective observational study. <i>Journal of Physical Therapy Science</i> , 2019 , 31, 795-801	1	1
88	Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. <i>Human Pathology</i> , 2019 , 84, 142-149	3.7	22
87	The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer. <i>Medical Oncology</i> , 2018 , 35, 45	3.7	2
86	Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study. <i>Oncologist</i> , 2018 , 23, 1210-1217	5.7	9
85	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. <i>Cancer Science</i> , 2018 , 109, 2539-2548	6.9	24
84	Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 119-127	3.5	2
83	Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors. <i>Chemotherapy</i> , 2018 , 63, 181-189	3.2	3
82	Association Between Laryngopharyngeal Reflux and Radiation-induced Mucositis in Head and Neck Cancer. <i>Anticancer Research</i> , 2018 , 38, 477-480	2.3	1
81	Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis. <i>Thoracic Cancer</i> , 2018 , 9, 1699-1706	3.2	3
80	A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. <i>Lung Cancer</i> , 2018 , 126, 41-47	5.9	21
79	Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 165-171	3.5	9

78	Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy. <i>Chemotherapy</i> , 2017 , 62, 205-213	3.2	8
77	Clinical significance of post-progression survival in lung cancer. <i>Thoracic Cancer</i> , 2017 , 8, 379-386	3.2	35
76	High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma. <i>International Journal of Clinical Oncology</i> , 2017 , 22, 872-879	4.2	6
75	Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 209-213	3.5	6
74	Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study. <i>BMC Cancer</i> , 2017 , 17, 800	4.8	34
73	A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 615-622	3.5	9
72	Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 497-505	3.5	15
71	Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2017 , 14, 1123-1128	2.6	2
70	Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. <i>BMC Cancer</i> , 2017 , 17, 571	4.8	39
69	Prognostic effect of class III β -tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors. <i>Oncology Letters</i> , 2017 , 14, 2369-2378	2.6	4
68	Prognostic Significance of Diabetes Mellitus in Locally Advanced Non-small Cell Lung Cancer. <i>Kitakanto Medical Journal</i> , 2017 , 67, 87-88	0	
67	Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer. <i>Thoracic Cancer</i> , 2016 , 7, 655-662	3.2	11
66	Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2016 , 21, 240-247	4.2	3
65	Prognostic significance of GRP78/BiP expression in patients with Stage III/IV hypopharyngeal squamous cell carcinoma. <i>Neoplasma</i> , 2016 , 63, 477-83	3.3	7
64	Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide. <i>Canadian Respiratory Journal</i> , 2016 , 2016, 5405810	2.1	11
63	Decreasing expression of glucose-regulated protein GRP78/BiP as a significant prognostic predictor in patients with advanced laryngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016 , 38, 1539-44	4.2	11
62	Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma. <i>International Journal of Hematology</i> , 2015 , 101, 46-51	2.3	18
61	The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. <i>International Journal of Clinical Oncology</i> , 2015 , 20, 668-73	4.2	10

60	Primary malignant melanoma of the trachea: A case report. <i>Oncology Letters</i> , 2015 , 9, 657-660	2.6	5
59	Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 521-6	3.5	48
58	Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy. <i>SpringerPlus</i> , 2015 , 4, 152		5
57	First-line gefitinib treatment in elderly patients (aged \geq 5 years) with non-small cell lung cancer harboring EGFR mutations. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 761-9	3.5	14
56	Hydroxyurea-induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case. <i>Internal Medicine</i> , 2015 , 54, 3171-6	1.1	2
55	Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2015 , 15, 989	4.8	25
54	Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations. <i>Clinical and Translational Oncology</i> , 2015 , 17, 702-9	3.6	12
53	Recurrent intimal sarcoma mimicking pulmonary embolism. <i>Japanese Journal of Clinical Oncology</i> , 2015 , 45, 695-6	2.8	1
52	Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy. <i>Radiology and Oncology</i> , 2015 , 49, 409-15	3.8	6
51	Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. <i>Supportive Care in Cancer</i> , 2015 , 23, 1699-708	3.9	91
50	Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors. <i>American Journal of Translational Research (discontinued)</i> , 2015 , 7, 1161-71	3	23
49	Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2015 , 11, 606-11	1.2	8
48	Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. <i>Annals of Thoracic Medicine</i> , 2015 , 10, 61-6	2.2	26
47	Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. <i>BMC Cancer</i> , 2014 , 14, 18	4.8	24
46	Identification of actionable mutations in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2014 , 86, 35-40	5.9	18
45	Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation. <i>Annals of Oncology</i> , 2014 , 25, 1948-1953	10.3	28
44	Acidic pH increases cGMP accumulation through the OGR1/phospholipase C/Ca(2+)/neuronal NOS pathway in N1E-115 neuronal cells. <i>Cellular Signalling</i> , 2014 , 26, 2326-32	4.9	10
43	Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. <i>Medical Oncology</i> , 2014 , 31, 88	3.7	13

42	Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients. <i>Respiratory Investigation</i> , 2014 , 52, 101-6	3.4	5
41	Perianal metastasis of non-small cell lung cancer. <i>Internal Medicine</i> , 2014 , 53, 1149-52	1.1	5
40	Dramatic Response of S-1 Administration to Chemorefractory Advanced Thymic Cancer. <i>Chemotherapy</i> , 2014 , 60, 356-9	3.2	2
39	Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene. <i>Molecular and Clinical Oncology</i> , 2014 , 2, 731-736	1.6	18
38	Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. <i>Neoplasia</i> , 2014 , 61, 233-40	3.3	22
37	Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma. <i>British Journal of Cancer</i> , 2014 , 110, 2047-53	8.7	25
36	Multiplexed molecular profiling of lung cancer using pleural effusion. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1048-1052	8.9	31
35	Differences in the efficacy of S-1 monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014 , 5, 121-5	3.2	1
34	Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. <i>Oncogene</i> , 2013 , 32, 4034-42	9.2	42
33	Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine. <i>Chemotherapy</i> , 2013 , 59, 307-13	3.2	8
32	Outcome of platinum-based chemotherapy for non-small-cell lung cancer patients with pleural dissemination detected during surgery. <i>Molecular and Clinical Oncology</i> , 2013 , 1, 949-952	1.6	5
31	Clinical features of patients with invasive thymoma: A retrospective analysis of 61 cases. <i>Surgical Practice</i> , 2013 , 17, 140-148	0.4	2
30	Papillary squamous cell carcinoma of the trachea associated with human papillomavirus-18 infection. <i>Internal Medicine</i> , 2013 , 52, 2785-8	1.1	1
29	Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation. <i>Anticancer Research</i> , 2013 , 33, 3279-84	2.3	6
28	Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. <i>International Journal of Cancer</i> , 2012 , 130, 1733-44	7.5	65
27	Reversible posterior leukoencephalopathy syndrome after carboplatin and paclitaxel regimen for lung cancer. <i>Internal Medicine</i> , 2012 , 51, 911-5	1.1	8
26	Recurrence of mantle cell lymphoma occurring in the tracheobronchial wall. <i>Internal Medicine</i> , 2012 , 51, 1143-4	1.1	2
25	Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 336-46	6.1	123

24	Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer. <i>Experimental and Therapeutic Medicine</i> , 2010 , 1, 799-808	2.1	25
23	Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010 , 68, 253-7	5.9	10
22	A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. <i>Lung Cancer</i> , 2010 , 69, 99-104	5.9	41
21	Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-methyl tyrosine uptake in outcome of non-small cell lung cancer. <i>Nuclear Medicine and Biology</i> , 2010 , 37, 911-6	2.1	22
20	Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer. <i>International Journal of Immunopathology and Pharmacology</i> , 2010 , 23, 153-64	3	24
19	Epigenetic inactivation of the thyroid hormone receptor beta1 gene at 3p24.2 in lung cancer. <i>Annals of Surgical Oncology</i> , 2010 , 17, 2222-8	3.1	28
18	Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. <i>Anticancer Research</i> , 2010 , 30, 4819-28	2.3	91
17	CXCR4+FOXP3+CD25+ lymphocytes accumulate in CXCL12-expressing malignant pleural mesothelioma. <i>International Journal of Immunopathology and Pharmacology</i> , 2009 , 22, 43-51	3	22
16	Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clinicopathological study. <i>International Journal of Cancer</i> , 2009 , 124, 1152-60	7.5	32
15	L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. <i>Journal of Surgical Oncology</i> , 2009 , 99, 433-8	2.8	37
14	L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. <i>Histopathology</i> , 2009 , 54, 804-13	7.3	43
13	Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. <i>Cancer Science</i> , 2009 , 100, 248-54	6.9	38
12	Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. <i>Cancer Science</i> , 2009 , 100, 753-8	6.9	46
11	CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. <i>Annals of Surgical Oncology</i> , 2009 , 16, 3473-81	3.1	56
10	Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2009 , 66, 120-6	5.9	59
9	Clinicopathological features of patients with bronchial-associated lymphoid tissue lymphoma. <i>Internal Medicine</i> , 2009 , 48, 301-6	1.1	27
8	L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. <i>Cancer Science</i> , 2008 , 99, 2380-6	6.9	105
7	Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III non-small cell lung cancer. <i>British Journal of Cancer</i> , 2008 , 98, 742-8	8.7	166

6	Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. <i>Pathology Research and Practice</i> , 2008 , 204, 553-61	3.4	49
5	Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. <i>Clinical Cancer Research</i> , 2007 , 13, 6369-78	12.9	90
4	A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2007 , 18, 471-6	2.4	12
3	A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007 , 30, 51-6	2.7	7
2	A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIa nonsmall cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007 , 30, 498-502	2.7	4
1	Management of malignant pericardial effusion with instillation of mitomycin C in non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005 , 35, 57-60	2.8	17